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SHORT COMMUNICATION
A new NFIA:RAF1 fusion activating the MAPK
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Pilocytic astrocytoma (PA) is one of the most common brain cancers among children and acti-
vation of the Mitogen-Activated Protein Kinase (MAPK) pathway is considered the hallmark. In
the majority of cases, oncogenic BRAF fusions or BRAF V600E mutations are observed, while
RAF1 or NF1 alterations are more rarely found. However, in some cases, no apparent cancer
driver events can be identified. Here, we describe a novel fusion between the transcription factor
nuclear factor 1A (NFIA) and Raf-1 proto-oncogene (RAF1) in a 5-year old boy with PA. The novel
fusion was identified as part of a comprehensive genomic tumor profiling. We show that the
NFIA:RAF1 fusion results in constitutive Raf1 kinase activity, leading to activation of down-
stream MEK1/2 cascade and increased proliferation of cancer cells. The NFIA:RAF1 fusion displayed
distinct subcellular localization towards the plasma membrane indicative of Raf-1 activation, in
contrast to both wild type NFIA and Raf-1, which were localized in the nucleus and cytoplasm,
respectively. In conclusion, our data support the existence of rare oncogenic RAF1 fusions with
constitutive Raf-1 activity. This highlights the need for broad genetic testing in order to refine di-
agnostics of PA and to unravel potential treatment options, e.g. with MEK inhibitors.
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Introduction
Pilocytic astrocytoma (PA) is the second most common pe-
diatric cancer diagnosis, constituting about 20% of all pediatric
brain tumors and the most common central nervous system
tumor (CNS) in the 5–19 year olds (1). PA has a peak inci-
dence in the 0–9 year age group and a favorable 10-year
overall survival of around 90% (1–3). The majority of PAs arise
in the cerebellum, but a second frequent site is the supra-
tentorial midline, including the optic pathways and the
hypothalamic/thalamic regions. PAs are generally slow-
growing, classified as World Health Organization (WHO) grade
I, and when possible, surgical resection is the treatment of
choice, leading to up to 90% progression free survival for cer-
ebellar sites with an achieved complete resection. In case of
non- or partially resectable tumors, which constitute the ma-
jority of the tumors of the supratentorial midline, many will
progress and need non-surgical treatment to control tumor
growth and symptoms (4,5). Although PAs are characterized
by distinct histologic features, i.e. circumscribed tumors with
bipolar cells with long pilocytic processes and Rosenthal fibers,
some may show histopathological features resembling gliomas
of higher grades, thus making diagnosis of PA challenging (6,7).
Extensive research has recently revealed that the molec-
ular mechanisms leading to PA are associated with the MAPK
signaling pathway and constitutive activation is considered the
unifying molecular feature of PA (8,9). The most common
genetic alterations involve the BRAF gene constituting about
80% of all PA cases, where chromosomal rearrangements (e.g.
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KIAA1549:BRAF or FAM131B:BRAF) or BRAF mutations are
found (10). In addition, mutations in KRAS and in NF1 have
been identified in PA. Previously, no genetic alterations in the
MAPK pathway were identified in around one fifth of the PA
patients. However, recent high throughput molecular analy-
sis for somatic screening of PAs has revealed novel alterations
in FGFR1 and NTRK2, supporting that the genetic altera-
tions in PA are solely linked to the MAPK pathway (9,11). More
recently, a fusion between SRGAP3:RAF1 was identified in
a PA patient, showing that translocations involved in PA are
not limited to the BRAF gene (11).
Materials and methods
Case report
A boy was diagnosed just before his two-year birthday with
diencephalic syndrome, severe behavioral disturbance and a
large supratentorial midline tumor involving the hypothala-
mus, basal ganglia and medial temporal lobes bilaterally,
measuring 7 × 3.8 cm. An open biopsy was performed, leading
to the diagnosis of PA WHO grade 1. To manage the dien-
cephalic syndrome, a percutaneous endoscopic gastrostomy
tube was inserted and he was initially treated with vincristine-
carboplatin-etoposide. Due to tumor progression, treatment
was changed after six months to vincristine-cyclophosphamide-
cisplatin, leading to six months of stable disease. However,
after 12 months of therapy the tumor progressed, necessi-
tating placement of a bi-frontal ventriculo-peritoneal shunt.
Therapy was changed to vinblastine in combination with
bevacizumab, which led to both clinical and radiological im-
provements but progression occurred within 18 months upon
initiation of vinblastin-avastin therapy.
Identification and verification of the NFIA:RAF1
fusion
RNA was purified from tumor tissue preserved in RNALater
(Life Technologies) using total AllPrep DNA/RNA purification
kit (Qiagen) and RNA-sequencing was done using TruSeq
Stranded Total RNA Library Prep Kit and sequenced on a
HiSeq2500 (Illumina). FusionMap bioinformatics tool was
used for screening of fusion transcripts (12). Verification by
RT-PCR was performed (Primer sequences are available
on request). An in-house non-CNS tumor was used as
negative control. RT-PCR product was sequenced by Sanger
sequencing using an ABI 3730 DNA Analyzer (Applied
Biosystems).
Molecular characterization of the NFIA:RAF1
fusion
HEK293 cells were cultured in DMEM supplied with 10% FBS
and penicillin/streptomycin (Invitrogen) and seeded in 6-well
plates. Cells were transfected with empty vector, EV (pCMV6-
Entry-FLAG, Origene), wild type NFIA (pCMV6-NFIA-FLAG,
Origene), wild type RAF1 (pCMV6-RAF1-FLAG, Origene),
NFIA:RAF1 (cDNA cloned into pCMV6-Entry-FLAG) (Primer
sequences are available on request). Transfection was done
using FuGene Transfection Reagent (Promega) according to
manufacturer’s recommendations. At 24 hours following trans-
fection, western blot analysis was performed as previously
described (13) with antibodies against Raf-1 (#12552; Cell Sig-
naling Technologies) and GAPDH (sc-22778, Santa Cruz
Biotecnologies). Transfected HEK293 cells were stimulated
for 10 minutes with 10 ng/ml human recombinant epidermal
growth factor (EGF) (R&D Systems), and western blot anal-
ysis was performed using antibodies against phospho-Ser221-
MEK1/2 (#2338; Cell Signaling Technologies), MEK1/2 (#8728;
Cell Signaling Technologies). HeLa cells were cultured in
DMEM supplied with 1 mM sodium pyruvate, 10% FBS and
penicillin/streptomycin (Invitrogen) and seeded in 96-well plates
in growth medium without FBS for serum starvation. Cells were
transfected using FuGene Transfection Reagent (Promega)
and 3 days after transfection, cell growth was measured with
MTT assay (Roche). Cell growth was calculated relative to
EV transfected cells.
Subcellular protein fractionation analysis
HeLa cells were plated at 30% confluency in 6-well dishes
and were transfected 6 hours after with pcDNA6-FLAG-
RAF1 or pcDNA6-FLAG-NFIA-RAF1 constructs using FuGene
(Promega) following the manufacturers protocol. After 48 hours
cells were collected and cytoplasmic and membrane subcel-
lular protein fractionation was performed using Cytoplasmic
Extraction Buffer (CEB) and Membrane Extraction Buffer (MEB)
from Subcellular Protein Fractionation Kit for Cultured Cells
(Thermo Fisher Scientific). Samples were analyzed by Western
Blot using anti-FLAG M2 antibody (Sigma).
Microscopy for subcellular localization
HeLa cells were plated at 40% confluency in 35 mm No. 1.5
coverglass Glass Bottom Microwell Dishes (MatTek
Corporation) and transfected after 6 hours with pCMV6-Entry-
NFIA-FLAG, pCMV6-Entry-RAF1-FLAG or pCMV6-Entry-
NFIA:RAF1-FLAG constructs using FuGene Transfection
Reagent (Promega). After 24 hours, cells were fixed in 4%
paraformaldehyde for 15 minutes, permeabilized in 0.1% Triton
X-100 for 10 minutes, incubated with Image-iT FX Signal En-
hancer (Thermo Fisher Scientific) for 30 minutes and blocked
in 3% BSA 0.1% Triton X-100 for 1 hour at room tempera-
ture. Dishes were then incubated with 1:10,000 mouse
monoclonal anti-FLAG M2 antibody (Sigma) overnight at 4 °C.
The day after, samples were incubated with 1:1000 second-
ary donkey anti-mouse Alexa Fluor 488 (Thermo Fisher
Scientific) and Alexa Fluor 568 Phalloidin (Thermo Fisher Sci-
entific) for 1 hour at room temperature. Fluoroshield with DAPI
mounting media (Sigma) was added to the dishes and images
were acquired with Zeiss ELYRA PS.1 LSM780 microscope.
The experiment was repeated using HEK293 cells (data not
shown due to suboptimal adherence of cells to cover glass
dishes).
Results and discussion
In search for a targeted treatment, the patient was stereo-
tactically re-biopsied and comprehensive genomic profiling was
carried out to unravel the genetic alterations driving the neo-
plastic growth in this patient. The comprehensive genomic
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profiling included whole exome sequencing of purified tumor
DNA (SureSelect Illumina), SNP array (Affymetrix), methyla-
tion array (450K Illumina) and purified tumor RNA was
subjected to RNA sequencing (RNA-Seq Illumina strand spe-
cific) and expression array (Affymetrix U133 plus 2.0). Initial
screening for common genetic alterations in PA (BRAF, KRAS,
NF1) was negative. However, a broad search for fusion tran-
scripts based on RNA-Seq data revealed a novel fusion
between the transcription factor nuclear factor 1A (NFIA) and
Raf-1 proto-oncogene (RAF1). A translocation between the
chromosomal regions 1q31.3 and 3p25.2 was identified, re-
sulting in fusion between NFIA exons 1–6 and RAF1 exons
9–17, including the complete coding sequence of the Raf1
kinase domain (Figure 1a). The breakpoint region was vali-
dated by Sanger sequencing (Figure 1b and c). In comparison,
the breakpoint between the previously identified fusion
SRGAP3:RAF1 is located by joining exons 1–12 of SRGAP3
to exons 10–17 of RAF1 (11). The srGAP3:Raf-1 fusion protein
was demonstrated to be hyperactive, presumably by a mo-
lecular mechanism involving lack of the N-terminal auto-
inhibitory region of Raf-1 (11,14), pointing to a similar
mechanism of action for the NFIA:Raf-1 fusion protein.
To explore the expression level of RAF1 mRNA in the PA
specimen in comparison with other PA expression profiles, we
examined two large online available datasets containing HG-
U133_Plus_2 expression array data from 47 (E-GEOD-
73066) and 49 (E-GEOD-44971) PA patients, respectively
(15,16). RAF1 was not differentially expressed (data not
shown), indicating that activation of Raf-1, rather than its
overexpression, is the cancer driver event in the patient. Hence,
we sought to clarify if the NFIA:RAF1 fusion results in con-
stitutive activity of Raf-1. HEK293 cells were transfected with
wild type NFIA, wild type RAF1, or the NFIA:RAF1 fusion gene
(Figure 2a). To explore if the fusion protein causes in-
creased Raf-1 kinase activity, we examined the phosphorylation
of MEK1, a Raf-1 substrate. Elevated phosphorylation of en-
dogenous MEK1/2 was observed in the NFIA:RAF1 transfected
cells, compared to cells with either of the fusion partners
(Figure 2b). The phosphorylation caused by the fusion was
shown to be equally potent as treatment of HEK293 cells with
epidermal growth factor (EGF), a well-described activator of
the MAKP pathway (17) (Figure 2b), demonstrating that the
NFIA:RAF1 fusion results in a constitutive activation of the
MAPK pathway. To investigate if the AKT/mTOR pathway was
equally activated by the fusion protein, western blot analysis
of phospho-S6 was performed after transfection; however, these
results did not reveal any significant changes in S6 phos-
phorylation levels (data not shown), supporting the notion that
the NFIA:Raf-1 fusion protein primarily activates the MAPK
pathway. To determine the effect of the fusion on cell growth,
we performed an in vitro proliferation assay, showing a sig-
nificant increase in cell growth of cancer cells transfected with
the fusion (Figure 2c). MAPK pathway activation by EGF stim-
ulation of serum starved HeLa cells resulted in 2.3-fold growth
stimulation (data not shown).
To further characterize the novel fusion protein, we ex-
plored the subcellular localization of the NFIA:Raf-1 protein.
By performing fractionation of the cytoplasmic and mem-
brane components in transfected HeLa cells, it was evident
that while wild type Raf1 kinase was enriched in the cyto-
plasmic fraction, the NFIA:Raf-1 fusion was clearly enriched
in the membrane fraction (Figure 2d). Immunofluorescence
microscopy was used to further investigate the subcellular lo-
calization of the different constructs. The transcription factor
NFIA was localized in the nucleus (Figure 2e), while wild type
Raf-1 was located in the cytoplasm (Figure 2f). Interestingly,
it was confirmed that NFIA:Raf-1 fusion protein displayed dis-
tinct subcellular localization with accumulation towards the
plasma membrane (Figure 2g), supporting the notion of con-
stitutive Raf-1 activation in the fusion as it has previously been
demonstrated that activated Raf-1 is recruited to the mem-
brane (18,19).
It is well established that PAs harbor the KIAA1549:BRAF
fusion and the majority of the cerebellar (80%) versus
noncerebellar (50–55%) PAs are driven by this fusion (20).
In line with this distribution, our novel NFIA:RAF1 fusion was
identified in a noncerebellar PA. Our findings of a novel RAF1
fusion and its relation to constitutive MEK activation support
the role of MAPK pathway as a key player in the tumorigen-
esis of PA, as well as contribute to the current knowledge and
molecular complexity of oncogenes in PA. To ensure an op-
timized and tailored treatment, it is crucial to substantiate the
different genetic alterations within the MAPK pathway. To
unravel the remaining 20–50% that do not harbor the fre-
quent KIAA1549:BRAF fusion, wide molecular screening, i.e.
DNA and RNA-sequencing, and SNP-array should be carried
out on therapy resistant cases. The identification of the novel
NFIA:RAF1 fusion gene emphasizes the feasibility of com-
prehensive genomic profiling for identification of rational
treatment targets (21). Therapy with MEK inhibitors, which are
currently in clinical phase 1 and phase 2 trials (22), provides
hope for precision medicine for the patients suffering from a
more rare PA with e.g. RAF1 alterations. Our patient, who is
now 6 years old, was not eligible for open European MEK in-
hibitor trials, but was granted treatment with the MEK inhibitor
trametinib on a compassionate use. Results from the MRI scan
Figure 1 Identification of a novel NFIA:RAF1 fusion in pilocytic
astrocytoma. (a) Graphic illustration of translocation between the
chromosomal regions 1q31.3 and 3p25.2, resulting in fusion
between NFIA (NM_001134673.3) exons 1–6 and RAF1
(NM_002880.3) exons 9–17, including the Raf-1 kinase domain.
(b) RT-PCR with primers in NFIA exon 6 and RAF1 exon 9 re-
sulted in a 406 bp PCR product. An in-house non-CNS tumor was
used as negative control. (c) The junction was verified by Sanger
sequencing of the RT-PCR product.
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Figure 2 Functional characterization and subcellular localization of NFIA:RAF1 fusion. (a) HEK293 cells were transfected with empty
vector, EV (pCMV6-Entry-FLAG), wild type NFIA (pCMV6-NFIA-FLAG), wild type RAF1 (pCMV6-RAF1-FLAG), NFIA:RAF1 (cDNA
cloned into pCMV6-Entry-FLAG). Western blot analysis was performed using antibodies against Raf-1 and GAPDH. The molecular
weight of the fusion protein was calculated to 80 kDa, while the endogenous Raf-1 is 75 kDa as depicted. (b) HEK293 cells were
transfected as described above, or stimulated for 10 minutes with 10 ng/ml human recombinant epidermal growth factor (EGF) as
positive control for activated MAPK pathway. Antibodies against phospho-Ser221-MEK1/2, MEK1/2 were used. (c) Cell growth of trans-
fected HeLa cells was measured 3 days after transfection. Cell growth is calculated relative to EV transfected cells. Error bars shown
are standard error of the mean (SEM) and the asterisk denotes statistical significance (P = 0.049) compared to EV. (d) HeLa cells
were transfected with EV, wild type RAF1 or NFIA:RAF1 constructs and fractionation into cytoplasmic and membrane fractions was
performed as described in the Materials and Methods section. Western blotting was performed using an antibody against FLAG-tag.
(e–g) Transfected HeLa cells were fixed and stained for FLAG-tag (green) indicating the FLAG-tagged constructs; NFIA-FLAG, RAF1-
FLAG and NFIA:RAF1-FLAG, F-actin (red), reflecting the localization of the cellular membrane and nucleus (blue). (For interpretation
of the references to color in this figure legend, the reader is referred to the web version of this article.)
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three and six months after initiating trametinib showed stable
disease and the treatment is currently ongoing.
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